ZFIN Image: Yan et al., 2021, Figure 5.

Image

Figure Caption

Figure 5.

Quantifying APEC immunotherapy responses and target specificity in human breast cancers in vivo. (A) Schematic of APEC antibody. (B) Experimental design. EpCAM⁻/mCherry⁺ MDA–MB-231 breast cells compared with those engineered to express EpCAM (EpCAM⁺/GFP⁺). (C) 3D volumetric renderings of breast cancer cells engrafted into the periocular musculature (6 dpt, pretreatment) and following IP injection with CMV-specific T cells administered with either control EpCAM antibody (control) or EpCAM-MC (EpCAM). (D and E) High-magnification 3D modeling comparing location of T cells in control (D) and EpCAM-MC–treated animal (E) at 11 dpt. Arrows denote CFSE-stained T cells that directly contact GFP⁺ tumor cells. (F) Quantification of fluorescent tumor cell number before and after treatment (n > 566 tumor cells/time point, n = 5 animals/condition, 0.1 mm³ volume). (G) Percentage of T cells that directly contacted EpCAM⁺/GFP⁺ or EpCAM⁻/mCherry⁺ tumor cells (n = 5 animals/condition; error bars denote ±SD, 0.0125 mm³ volume). ***, P < 0.001, χ² test (F) and Student’s t test (G). Scale bar equals 10 µm (C–E).

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Med.